Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $116.2 million.

  • Xeris Biopharma Holdings' Total Current Liabilities rose 27.67% to $116.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.2 million, marking a year-over-year increase of 27.67%. This contributed to the annual value of $100.4 million for FY2024, which is 5.52% up from last year.
  • Xeris Biopharma Holdings' Total Current Liabilities amounted to $116.2 million in Q3 2025, which was up 22.10% from $95.2 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Total Current Liabilities ranged from a high of $116.2 million in Q3 2025 and a low of $37.3 million during Q3 2021.
  • For the 3-year period, Xeris Biopharma Holdings' Total Current Liabilities averaged around $90.0 million, with its median value being $91.0 million (2024).
  • In the last 5 years, Xeris Biopharma Holdings' Total Current Liabilities soared by 180.21% in 2021 and then dropped by 10.24% in 2024.
  • Over the past 5 years, Xeris Biopharma Holdings' Total Current Liabilities (Quarterly) stood at $79.0 million in 2021, then declined by 6.86% to $73.6 million in 2022, then rose by 29.30% to $95.2 million in 2023, then increased by 5.52% to $100.4 million in 2024, then rose by 27.67% to $116.2 million in 2025.
  • Its last three reported values are $116.2 million in Q3 2025, $95.2 million for Q2 2025, and $95.1 million during Q1 2025.